The SAVI has gained widespread use for accelerated partial breast irradiation (APBI) brachytherapy. Treatments with SAVI produce inherent heterogeneities including variable backscatter due to proximity to the tissue-air interface and variable cavity contents, causing inaccuracy in the dose calculation. In this study, a model of SAVI with sources of 169Yb developed recently was defined and simulations with MCNP4C code of Monte Carlo were performed through different scenarios to assess the effects of these heterogeneities on the dose distribution. The results showed that the dose delivered to target volume may be lower than the planned dose by up to 9–16%. Therefore, the therapy with169Yb must be viewed with caution and a correction factor must be applied in treatment planning systems. It was also observed that the presence of air cavity changed the relative dose 1% for a symmetric plan compared to a water cavity and up to 5% for an asymmetric plan. It was indicated that the dose modification factor (DMF) did not differ in any significant way to that of the symmetric plan. The effect of the composition on the DMF was negligible because the natures of water and breast tissue were approximately similar. All the obtained results indicated that should 169Yb sources be used with SAVI applications, some amendments of treatment planning systems would be employed.
Australasian Physical & Engineering Sciences in Medicine – Springer Journals
Published: May 13, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera